Compare Cytokinetics Inc (CYTK) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs PAGSEG Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while PAGSEG Inc trades at $10.79 (market cap $2.94B). The key difference: Cytokinetics Inc is far larger — about 2.9× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and PAGSEG Inc for 26 Days on average.
| CYTK | PAGS | |
|---|---|---|
Market Cap | $8.62B | $2.94B |
Volume | 2,594,626 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $87.26 | $12.00 |
52-Week Low | $54.76 | $8.44 |
Typical Hold Time | 19 Days | 26 Days |
Enterprise Value | $8.72B | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong profitability with a 10.45% net income margin and trades at a discounted valuation with a P/E of 7.1 and P/S of 0.74. Recent earnings beat expectations in Q2 2026, and a $0.28 dividend is scheduled for September 2026.
The outlook is positive given undervaluation, profitability, and dividend yield, but risks include a recent earnings miss in Q1 2026 and a projected negative net cash flow for 2026. Investor sentiment is supported by strong analyst buy ratings, though technical indicators show some overbought conditions with RSI at 78.08.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
